Editor 's not e: This article on the embryo logy of the fa cial nerve and related structures is the second ofa twopart series. Pa rt I, which covered the phylogeny of the f acial nerve and related structures, appeared in the September issue.J
Introduction
In studying the embryology of the facial nerve, It IS helpful to keep in mind the fin al structure tow ard which development progresses. In the adult, the motor nucleus of the facial nerve (VIIIth cranial nerve ) is located deep in the reticular formation of the caudal portion of the pons. The axons leave the moto r nucleu s and extend dor sally and medially, cranially and superficially.They bend around the abducens nucleus to form the first genu of the facial ner ve. The fibers then course deep through the pon s and exit from the central nervous system between the olive and the inferior cerebellar peduncle. At this point, the axon s join to form the motor root. The sen sory root (nervus intermedius) con sists of central processes of neurons located in the geniculate ganglion and axons of par asympathetic neurons from the superior saliv atory nucleus. The nervus intermedius enters the central nervous system at the pontocerebellar groove lateral to the moto r root and synapses with neurons in the upper part of the solitary tract of the medulla oblongata. The facial nerve and nervus intermedius course with the vestibuloacoustic nerve from the brainstem and ent er the internal auditory canal (figure I). For approximately 20 % of its course, the nervu s intermedius is fused with the VIIIth cranial nerve."
At the point whe re the facial nerve enters the middl e ear, it bend s a second time at the geniculate ganglion (the second genu) and courses horizontally through the middle ear. It then curves (the pyramidal bend) to course vertically throu gh the mastoid bone and exits at the stylomastoid for amen (figure 2). The nerve is ordin aril y surrounded by a bon y sheath call ed the fallopian canal. Several branches are given off during the intrapetrosal course. Th e faci al ner ve spreads extr atemporally to innervate the facial mu scul atur e (figure 3).
Medi ally to laterally, the fac ial ner ve branches include II struc tures of note (figure 4): • the greater superficial petros al nerve, which supplies taste fiber s to the palatal mucosa , preganglionic parasympathetic axons to the pterygopalatine ganglion, and postganglionic axons to the lacrimal glands, nasal glands, and palatine mucosal glands; it also commun icates with the lesser petrosal nerve? • the nerve to the stapedius muscle • the chorda tympani nerve, which supplies taste fibers to the anterior two-third s of the tongue, preganglionic parasympathetic fibers to the submandibular gland, and postganglionic fibers to the submandibular and sublingual glands • the posterior auricular branch-which innervates the auricularis posterior, the crani ally oriented muscles of the auricle, and the occipital musclescommunicates with the greater auricular nerve, the auricular branch of the vagus nerve, and the lesser occipital nerve' • the branch to the posterior belly of the digastric muscle • the branch to the stylohyoid muscle • the temporal branch that supplies the lateral intrinsic muscle of the auricle, the anterior and superior auricular muscles, the frontalis, the orbiculari s oculi, and the corrugator • the buccal branch , which innervates the proceru s, the zygomaticus major and minor , the levator labii superioris, the levator anguli oris, nasal muscles, the buccinator, and the orbicularis oris • the marginalm andibular branch to the risorius muscle and the muscles of the lower lip and chin • the cervical branch to the platysma; there are interconnections between the facial nerve and primarily the sensory nerves, including the trigeminal , glossopharyngeal, vagus, and cervical nerves'
The intracranial portion of the facial nerve is supplied by the anterior inferior cerebellar artery . The intrapetrosal portion is supplied by the superficial petrosal branch of the middle meninge al artery and the stylomastoid branch of the posterior auricular artery. The extracranial portion is suppl ied by the stylomastoid, posterior auricular, superficial tempor al, and transverse facial arterie s. The anastomosis between the intratemporal branche s usually occurs in the upper one-third of the vertic al portion.
Embryology of the intracranial portion of the facial nerve
This discussion include s information on the development of only the extracranial portions of the facial nerve. We encourage the reader to consult other literature for a brief review of the embryology of the intracranial portion s.' This information is very helpful for the purpose of orientation .
Fertilization through week 4 . The facio-acoustic primordium appears during the third week of life. It is attached to the metenc ephalon ju st rostral to the otic vesicle. It become s more superficial and rostral as it proceeds ventrally , and it ends adjacent to the deep surface of the epibranchi al placode on the dorsal and caudal aspect of the first branchial groove. There are no branches, and the geniculate ganglion is not yet present ( figure 5 ). During the fourth week, by the time the embr yo reaches 4.8 mm in length , the facial nerve splits into two parts. The chorda tympani nerve comes off rostrally, courses ventrally to the first pharyngeal pouch , and enters the mandibular arch. The caudal main trunk terminates in mesenchym e. By the time the embryo reaches 6 mm in length, the nerve approaches the epibr anchi al placode, and large, dark nucle i mark the development of the geniculate ganglion. ' Weeks 5 and 6. By the time the embryo has reached 7 mm in length, near the beginn ing of the fifth week, the mesenchymal concentrations that form the cephalic muscles can be seen in assoc iation with their nerves (figure 6). 6 The geniculate ganglion and the nervus intermedius also appear, although the latter is not always visible as a separate nerve until approximately the seventh week.' The geniculate ganglion is lateral and rostral to the VIIIth nerve ganglion. The greater superficial petrosal nerve is present. The chord a tympani is large and enters the mandibul ar arch; it terminates near a branch of the mandibul ar nerve, which will become the lingual nerve. By the middle of the fifth week (embryo length : 10 mm), the facial nerve gives off small branches to the posterior digastric premu scle mass. The nerve termin ates in mesenchym e. as 55years.Thema jority ofpatients werebetween40and 69 years (70%), 16% were 70 years and ol der and 14% were younger than 40 years of age. Of these patient s, 161/629(89/ 376receivingpil ocarpine) were over theageof 65 years.The adverse event s report ed by those over 65 years and those 65 yearsand younger were comparable except fornotabletrendsfor urinary frequency,diarrhea,and dizziness.The incidences of uri naryfrequency and diarrhea in theelderly were about double those in the non-elderly. The incidenceof dizziness was about3 times ashighinthe elderly as in the non-elderly. These adver se experiences were not considered to be serious. In the 2 pl acebocontrolledstuoies,themostcommonadverseevent srel ated to drug use were sweating, uri naryfrequency, chills, and vasodilatation (flushing). The most commonly reported reason for patient disconti nuation of treatment was sweating. Expected pharmacologic effects of pil ocarpine include the followingadverse experiences associated with SALAGEN'Tablets : Drug Interactions: Pilocarpineshouldbeadministeredwith caution to patients taking beta adrenergic antagonists becauseofthepossibilityofconductiondisturbances.Drugs wtth parasympathomimet ic effeclsadministeredconcurrently with pilocarpine would be expected to result in additive pharmacol ogic effects. Pilocarpine might antagonize the anti cholinergic effects of drugsused concomitantly. These effects should be considered when anticholi nergic properties may becontributing to the therapeutic effect of concomitant medication(e.g.,atropine, Inhaledipratropium). Whil e no formal drug interaction studies have been pert ormed,thefoll owingconcomitant drugs were used inat least 10% of patients in either or bot h Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydr oxychl oroquine SUlfate, ibuprofe n, levothyroxine sodium, medroxypr ogesterone acetate, methotrexate, mul tivitamins, naproxen, omeprazole, paracetamol,and prednisone.
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Carcinogenesis, Mutagenesis, Impairmenl of Ferti lity: Li fetimeoral carcinogenicity studies were conducted inCOl miceand Sprague-Dawleyrats.Pilocarpinedi d notinduce tumors in mice at anydosagestudied(upto30mglkg/day, whichyielded a sys temicexposureapproximately 50 times larger than the maximum systemic exposure observed clinically). Inrats, a dosage of 18 mglkg/day , which yielded a systemic exposure approximately 100 times larger than the maximum systemic exposure observed cli nically, resultedinastatisticallysignificant increase intheincidence of benign pheochromocytomas in both malesand females, and a statistically signi ficant increasein the incidence of hepatocellular adenomas infemal e rats.Thetumorigenicity observedinratswas observed onlyatalargemultipl eof the maximumlabeled cl inical dose, and may notbe relevant to clin ical use. No evidence that pi locarpine has the potential to cause genetic toxicity was obtained in a series of studies that included: 1) bacterial assays (Salmonella and E. col i) for reverse gene mutations; 2) an in vit ro chromosome aberration assay in a Chinese hamster ovarycellline; 3)an invivochromosome aberration assay (micronucleus test) In mice; and 4) a primary DNA damage assay (unscheduled DNAsynthesis) inrathepatocyt e pri marycul tures. Or al administrationof pil ocarpineto mal eandfemal e ratsat adosageof18 mglkg/day,whichyieldedasystemicexposure approximately 100timeslarger thanthemaximumsystemic exposure observed clinicall y, resulted in impaired reproductive function, includingreducedfertility, decreased sperm motility, and morphol ogic evidence of abnormal sperm. Itisuncl earwhether thereductioninfertilitywas due to effectson mal e animals, femal e animals, or bothmales and femal es. In dogs, exposure to pilocarpine at a dosage of 3 mglkg/day (approximately 3 times the maximum recommended humandose whencomparedonthebasi sof body surtacearea (mg/ m) estimates) for 6 monthsresul ted inevidence of impairedspermatogenesis.The dataobt ai ned in these studies suggest that pilocarpine may Impair the fertility of mal e and femal e humans. SALAGEN' Tablets shouldbeadmi nisteredto individual swhoare attempt ingto conceiveachildonlyif thepotentialbenefitjustifiespot ential impairment offert ility.
Pregnancy: Teralogenic Effects Pregnancy Calegory C:Pi locarpinewasassociatedwith a reductioninthe mean fetal bodyweightand an increase in the incidence ofskeletal variat ionswhen given to pregnant rats at a dosageof 90 mglkg/day (apprOXimately 26times themaximum recommendeddosefora 50 kghumanwhen compared on the basis of body surtace area (mg/ m') est imates). These effects may have been secondary to maternal toxicity. In another study, oral admi nistration of pi locarpi netofemaleratsduringgestationand lactationata dosage of 36 mglkg/day (approximately 10 times Ihe maximum recommended dose for a 50 kg human when compared on the basis of body surtace area (mg/m') estima tes) resultedin an increased incidence of stillbi rths; decreased neonatal survival andreducedmeanbody weight of pups wer e observed at dosages of 18 mglkg/day (approximately 5 times the maximum recommendeddose for a 50 kg humanwhen comparedonthe basis of body surtace area (mg/ m') est imates) and above. There are no adequate and well-contronec sfucies in pregnant women. SALAGEN ' Tablets shoul d be used during pregnancyonl y if thepotentialbenefit justifies thepotential risk tothefetus.
Nursing Molhers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious AdverseEvenl adverse reactionsinnur singinfantsfromSALAGEN' Tablets, a decision should be made whether todiscontinue nur sing or to discontinue the drug, taking into account the import anceof the drug tothe mother. INDICATIONS AND USAGE: SALAGEN ' Tablets are indicated for 1)the treatment of symptoms of dry mouth fromsalivarygland hypofunctioncaused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptomsofdrymouth inpatient swithSjogren'sSyndrome.
CONTRAINDICATlONS:SALAGEN' Tabletsarecontraindicated inpatientswithuncontrolledast hma, knownhypersensitivity topil ocarpine,andwhenmiosisisundesirable,e.g., inacute Iritis and in narrow-angle(angle closure)glaucoma.
WARNINGS:
Cardiovascul ar Di sease: Patients with significant cardiovascular disease may be unable to compensate for transientchanges in hemodynamicsor rhythm inducedby pilocarpine. Pulmonary edema has been report ed as a complication of pilocarpine toxicity from high ocular doses givenfor acute angle-closureglaucoma.Pilocarpine shoul d be administered with cautionin and under close medical supervision of patient s with si gnif icant cardiovascular disease.
Ocular: Ocular formulations of pilocarpine have been reported to cause visual blurring whi ch may result in decreasedvi sual acuity , especially at night and in patients withcentral lenschanges,and tocauseimpairmentofdepth perception.Caut ionshould beadvisedwhi ledriving at night or pert orminghazardousacti vities in reduced lighting.
Pulmonary Di sease: Pilocarpine has been report ed to increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Pilocarpine hydrochl oride should be administered with caution to and under close medical supervision in patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease requiringpharmacotherapy.
PRECAUTIONS:
General: Pil ocarpine toxicity is characte rized by an exaggeration of its parasympathomi metic effects. These may include: headache, visual disturbance, lacr imation, sweating, respi ratory distress, gastroi ntestinal spasm, nausea, vomiting, diarrh ea, atrioventricular block tachycardia,bradycardia,hypotension, hypert ension, ShOCk: mental confusion, cardiac arrhythmia, and tremors. The dose-rel ated cardiovascular pharmacologi c effects of pilocarpine include hypotension, hypert ensi on, bradycardia,andtachycardia. Pilocarpineshould beadministeredwith caution to patient s with known or suspected cholelithiasis or biliary tract disease. Contracti ons of the gallbladder or bili ary smooth muscle could precipitate complications including cholecystitis,cholangitis,and bili aryobst ruct ion. Pil ocarpine may incr ease ureteral smooth muscle tone and could theoret ically precipi tate renal col ic (or "ureteral reflux"), particularly in pat ient s with nephrolithiasis. Choliner gi c agonistsmayhavedose-related centr alnerv ous system effects. This should be consi dered when treating patientswi thunderl yingcognitiveor psychiatri c disturbances.
Hepatic Insufficiency: Based on decreased pl asma clearance observed in patients with moderate hepati c impairment, thestartingdose in these patients should be 5 mg twice daily , foll owed by adjustment based on ther apeut ic response and tolerability. Patients with mild hepatic insufficiency (Chil d-Pugh score of 5-6) do not requiredosage reductions.To date,pharmacokinetic studies in SUbjects with severe hepatic impairment (Chil d-Pugh score of 10-15) have not been carried out . The use of pil ocarpine inthese patients is notrecommended. ure 4 ).
In the 8-mm embr yo, all the cranial nerves except the olfactory and optic nerves are recognizable. All the cranial nerves that carry sensory fibers have prominent ganglia near their points of connection with the brain . These include cranial nerves V, VII, VIII, IX, and X. The primarily efferent cranial nerves (III, IV, VI, and XII) have no external ganglia . In the 8-to 14-mm period, the posterior auricular nerve appears near the chorda tympani. Complete separation of the facia l and acoustic nerves is apparent, and a discrete nerv us intermedius develops.
By the time the embryo reaches 14 mm in length, the genic ulate ganglion and the greater superficial petrosal nerve are well defined , and the epibranchial placode has disappeared.The greater superficial petrosal nerve courses ventrally and rostrally to the lateral aspect of the developing internal carotid artery . Here it join s the deep petrosal nerve and continues as the nerve of the pterygoid canal. It terminates in a group of cells that will become the pterygopalatine ganglion . At 16 to 17 mm (middle of the sixth week), a branch arises from the ventral aspect of the geniculate ganglion and courses caudally and dorsally to the glossopharyngeal ganglion. The chorda tympani and lingual nerves end near the developing submandibular ganglion. Some facial nerve fibers terminate in the mandibular arch superficially and caudally.
During this period , the superficial layer of the mesenchymallamina of the second arch spreads to establish four laminae (figure 7):
• the occipital lamina (the occipitalis, auricu laris posterior, and transverse nuchae muscles) perter Maxillary Nerve
Taste Fibers
When the embryo is between 10and 18 mm in length, the deep layer of the second mesenchymal lamina differentiates into the posterior digastric complex (the stapediu s muscle, the posterior belly of the digastric muscle, the digastric tendon , and the stylohyoid muscle).
Weeks 7 through 9. By the beginning of the seventh week , the embryo has reached approximately 18 mm in length ( figure 8 ). The nervus intermedius, which is smaller than the motor root of the facial nerve, passes into the brainstem between the acoustic nerve and the facial nerve moto r root. The chord a tympani and lingual nerves unite proximal to the submandibular gland. The postauricular nerve can be clearly seen di stal to the chorda tympani nerve s, and it divides into crani al and caudal branches.
The caudal branches communicate with branches of cervical nerves C2 and C3. Several branches are visible in the peripheral portion of the VIIth nerve . The most caud al branches communicate with nerves from the second and third cervical ganglia in a plexus in the second arch. Another portion courses ventrally, terminating deep to the platysma myobl astic lamina. The rest of the branches cour se to the angle of the mouth or caudally and superiorly into the mandibular arch. By the time the embryo is 19 mm long, some caudal branches have reached the infrao rbital rim. All of the peripheral branches lie close to the deep surfaces of the myoblastic laminae that will form the facial muscles. Very few fiber s course dorsally. The zygom atic and tempor al nerves will arise higher in the facial nerve'. At 18 mm, the parotid bud is rostral and unbranched, appearing as an evagination from the lateral oral cavity area.
In the 22-mm embryo (middle of the seventh week ), the posterior belly of the digastric muscle and the stapedius and stylohyoid muscl es are developing (figure 9). A branch from the geniculate ganglion near the greater superficial petro sal nerve , which developed earlier, is reduced to a communication as the tympanic plexus and the lesser petro sal nerve develop from the IXth cranial nerve. The interanastomoses of the peripheral branches of the facial nerve are visible as separation s of the main trunk . A small nerve branch appro aches the buccal region superficial to the parotid bud.
Separations between nerve branches increase considerably in number and size by the end of the seventh week (26 mm). By then , the branch to the stapedius muscle is 
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The superficial layer of the seco nd-arch mesenchyme differentiates into two more lamin ae:" Between 24 and 26 mm, the zygo maticus major , the depressor anguli oris, and the buccinator appear. Between 27 and 45 mm, the frontalis and zygomaticus minor appear. The branch that connects the VIIth cranial nerve with the lesser petro sal nerve (from cranial nerve IX) apparently carries small myelinated fibers that contain interspersed autonomic fibers from the auricular branch of cranial nerve X. In addition, by 26 mm the embryo develops first-order ductule s of the parotid primordium, which lies next to the masseter muscle, and severa l branches of the facial nerve course superficial to it. 7 By 27 mm, seco nd-order ductules appear. At this time, the buccal, marginal mandibul ar, and cervi cal nerve branches approac h the parotid primordium . By 32 mm (eighth week) , third-order ductul es are present, and the primordium has entered the parotid space . Inthe 37-mm embr yo also appear at approximately 37 mm. ' During the ninth week (50 to 60 mm) , the auricularis anterior, the corrugator supercilii, the occipital and mandibular platysma, and the levator labii superioris appear. Also about the ninth week, the laterohyale fuses to the otic capsule to form part of the anterior wall of the fallopian canal and the pyramidal eminence. The segment of the anterior wall of the fallopian canal distal to the laterohyale is formed by Reichert's cartilage. The cranial nerves move closer to their adult relationships. Weeks 10 through 15. During the 58-to 80-mm period, extensive branching of the peripheral portions of the facial nerve occurs ( figure 10 ). Some divisions reach the midline . Extensive communication with branches of the trigeminal nerve occurs in the perioral and infraorbital regions. Communications exist between the nervus intermedius and both the VIIIth nerve and the motor root of the VIIth nerve. Despite extensive branching, the facial nerve begins its vertical course while still in the middle ear, and its relationship to the external and middle ear structures is far more anterior than it is in the adult.
During the 11th week (80 mm) , the external petrosal nerve arises from the facial nerve distal to the geniculate ganglion and courses with a branch of the middle meningeal artery. Branches also arise from the facial nerve between the stapedius and the chorda tympani nerves. Together, these branches and branches of cranial nerves IX and X provide sensory innervation to the external auditory canal. Branches to the lateral aspects of the eyelids are present, and communication with the zygomaticotemporal nerve has begun to develop. Previous communications with branches of cervical nerves have now become communications with the lesser occipital and transverse cervical nerves . The horizontal portion of the facial nerve can be distinctly seen adjacent to the developing otic capsule. The nasal muscles are also differentiated at approximately 80 mm.
The relationship between the facial nerve and the parotid gland is about the same at 12 weeks as it was at 7 weeks. However, by the time the embryo reaches 80 mm in length, complicated connections between the superficial and deep portions of the parotid primordium can be seen .? At 14 or 15 weeks, the geniculate ganglion is fully developed, and facial nerve relationships to middle ear structures have developed more fully. During this growth period, the facial nerve has remained in association with the mesenchyme, which differentiates into the labyrinth and the mastoid . facial nerve, blood vessels , and stapedius muscle on the posterior aspect of the cartilaginous otic capsule. The sulcus is the beginning of the fallopian canal. The orbicularis oris, the levator anguli oris, and the orbicularis oculi 
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will occur in this region as the mastoid tip dev elops postnatally.
Clinical applications
In patients with congenital malformations, it is usually possible to determine the fet al age at which dev elopmental arrest occurred. This information allows the surg eon to predict the anatomy of the deformed ear and facial nerve on the bas is of their usual embryologic dev elopment at the time when the arrest occurred. Moreover, if anomalies are also present in other org an system s (e.g., the kidney), they oft en reflect inte rferenc e with development at the same time in fetal life. Hence, when a congenital anomaly of any portion of the ear can be obser ved visually, radiologically, or surgically , and if the clinician recognizes the fetal age at which normal development ceased in that portion, the phy sici an should be able to predict the po sition of the facial nerve. If the facial nerve is anomalous, its development is most likely to have been int errupted at the same time that the development of the ear was interrupted, particularly in the case of a middle ea r malformation.
To test the validity of such predi ctions, sur gical observations were mad e of 13 ea rs in II patient s with congeni- Week 16 through birth. Between 16 and 20 weeks, the facial nerve, arter ioles, venules, and the stapedius mus cle lie in a sulcus on the canalicular wa ll. The mesenchyme in whi ch the y are surrounded is differentiating into connective tissue. Although the middle ear continues to enlarge, the faci al ner ve rem ain s more super fici al and anterior in relation to the auricle than it is in the adult. All defin iti ve communicat ion s of the facial nerve are established by the 16th wee k (146 mm). By 26 wee ks, ossification has pro gre ssed, and growth of the outer layer of perioste al bone ha s resulted in a partial clo sure of the sulcus, forming the fallopian canal. The deep surface is completed first. By 35 week s, a bony ridge has formed that separates the geniculate ganglion from the epitympanic rim . Late in fetal life, the facial canal in mo st cases is closed by bone except in the anterior cranial portion, where it remain s open to form the facial hiatus along the floor of the middl e crani al fos sa. However, at least 25% of fallop ian canals have this dehi scence; the most common site is adj acent to the oval window." Th e length of the dehi scence rang es from 0.5 mm to the length of the entire horizontal port ion, but they are usu ally no larger than about 2 x 3 mm. Thi s mo st common area of dehiscence is probably secondary to the failu re of ossification after the stapedial artery (which passes through this area) resorb s prior to birth. The incidence of dehiscence has been reported to be as high as 55 %. 9 By the time of birth, the facial nerve has developed into a complex but generally con sistent structure. Of particular surgical interest is a study of the mandibular ramus in stillborns by Sammarco et al.'? They found that in 17 of 24 facial halves , some or all of the mandibular branches of the cer vical facial ramus were below the angle of the mand ible. Moreover , 19 of the 24 speci mens had 2 or 3 mandibul ar branches. All mandibular branches were above the mandibular margin as it cros sed the facial artery . In 16 specimens, all branches passed over the facial artery; in the other 8, they straddled the faci al artery . At birth, the anatomy of the facia l nerve approximates that of the adult with the exception of the nerve's exit through the superficially located stylomas toid for amen. Adult anato my 774
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